Enanta Pharmaceuticals (ENTA) Expected to Announce Quarterly Earnings on Wednesday

Enanta Pharmaceuticals (NASDAQ:ENTAGet Free Report) is projected to announce its earnings results before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of ($1.16) per share and revenue of $17.25 million for the quarter.

Enanta Pharmaceuticals (NASDAQ:ENTAGet Free Report) last released its earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The business had revenue of $14.60 million for the quarter, compared to analyst estimates of $17.99 million. During the same quarter in the previous year, the firm posted ($1.33) EPS. The business’s revenue for the quarter was down 22.8% on a year-over-year basis. On average, analysts expect Enanta Pharmaceuticals to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Enanta Pharmaceuticals Trading Down 3.4 %

NASDAQ ENTA opened at $5.12 on Wednesday. The stock has a market capitalization of $108.49 million, a price-to-earnings ratio of -0.93 and a beta of 0.56. The business’s 50 day moving average is $6.65 and its two-hundred day moving average is $10.33. Enanta Pharmaceuticals has a 12-month low of $4.71 and a 12-month high of $17.80.

Insider Buying and Selling at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of the stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.06, for a total transaction of $41,444.52. Following the sale, the chief executive officer now owns 801,638 shares in the company, valued at approximately $6,461,202.28. This represents a 0.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 13.64% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. HC Wainwright lowered their price target on Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, December 24th. Robert W. Baird lowered their price target on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, November 26th. Finally, JMP Securities restated a “market outperform” rating and issued a $21.00 price target (down previously from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $17.25.

View Our Latest Analysis on Enanta Pharmaceuticals

Enanta Pharmaceuticals Company Profile

(Get Free Report)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.

Featured Stories

Earnings History for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.